MNG767
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.580
- G2M_CHECKPOINT+0.543
- MYC_TARGETS_V1+0.503
- UNFOLDED_PROTEIN_RESPONSE+0.393
- MTORC1_SIGNALING+0.372
- OXIDATIVE_PHOSPHORYLATION+0.335
- MYC_TARGETS_V2+0.325
- PROTEIN_SECRETION+0.318
- INTERFERON_ALPHA_RESPONSE+0.245
- SPERMATOGENESIS+0.217
Top 10 suppressed
- MYOGENESIS-0.299
- WNT_BETA_CATENIN_SIGNALING-0.234
- HEDGEHOG_SIGNALING-0.223
- KRAS_SIGNALING_DN-0.199
- UV_RESPONSE_DN-0.170
- HYPOXIA-0.166
- TGF_BETA_SIGNALING-0.152
- COAGULATION-0.132
- APICAL_JUNCTION-0.130
- ESTROGEN_RESPONSE_EARLY-0.125
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 930630ee-1c36-4567-aeff-042eef1654e6 | — | — | 0.860 |
| 2 | TCGA-DK-A1A6-01A-11R-A13Y-07 | — | — | 0.860 |
| 3 | C3N-00294 | — | cohortA1 | 0.859 |
| 4 | BS_5CTVXVRX | high-grade glioma | — | 0.858 |
| 5 | SRR6013495 | — | cohortA1 | 0.855 |
| 6 | SRR12696741 | — | — | 0.848 |
| 7 | SRR10841996 | — | — | 0.844 |
| 8 | TCGA-38-4625-01A-01R-1206-07 | — | cohortA1 | 0.838 |
| 9 | SRR934912 | — | — | 0.834 |
| 10 | TCGA-05-4415-01A-22R-1858-07 | — | cohortA4 | 0.834 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.580 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.543 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.503 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.393 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.372 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.335 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.325 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.318 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.245 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.217 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.197 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.181 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.171 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.154 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.154 | Idelalisib | — uncovered |
| PEROXISOME | 0.154 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.148 | Inavolisib | — uncovered |
| COMPLEMENT | 0.132 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.115 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.103 | Inavolisib | — uncovered |